Cargando…

Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study

INTRODUCTION: Low-cost generic direct-acting antiviral (DAA) regimens for treatment of hepatitis C virus (HCV) are available in several low-income/middle-income countries, important for treatment scale-up. This study evaluated the cost-effectiveness of genotype-dependent and pan-genotypic DAA regime...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tasavon Gholamhoseini, Mohammad, Sharafi, Heidar, HL Borba, Helena, Alavian, Seyed Moayed, Sabermahani, Asma, Hajarizadeh, Behzad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Health Economics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9185662/ https://www.ncbi.nlm.nih.gov/pubmed/35676019 http://dx.doi.org/10.1136/bmjopen-2021-058757

Ejemplares similares

Treatment of hepatitis C virus infection with direct-acting antiviral agent-based regimens in Iranian patients with hereditary bleeding disorders
por: Sharafi, Heidar, et al.
Publicado: (2021)

Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals
por: Hesamizadeh, Khashayar, et al.
Publicado: (2016)

Appropriate Genotyping of Hepatitis B Virus in Iran
por: Jazayeri, Seyed Mohammad, et al.
Publicado: (2015)

Harm reduction program and hepatitis C prevalence in people who inject drugs (PWID) in Iran: an updated systematic review and cumulative meta-analysis
por: Rajabi, Abdolhalim, et al.
Publicado: (2021)

Real-life efficacy of generic sofosbuvir/ledipasvir for treatment of Iranian patients with chronic hepatitis C: A cohort study
por: Sharafi, Heidar, et al.
Publicado: (2020)

Harm reduction during the COVID-19 outbreak in Iran
por: Karimi-Sari, Hamidreza, et al.
Publicado: (2020)

IL28B polymorphism, Explanation for Different Responses to Therapy in Hepatitis C Patients
por: Sharafi, Heidar, et al.
Publicado: (2011)

Hepatitis C resistance to NS5A inhibitors: Is it going to be a problem?
por: Sharafi, Heidar, et al.
Publicado: (2018)

Molecular Tracing of Hepatitis C Virus Genotype 1 Isolates in Iran: A NS5B Phylogenetic Analysis with Systematic Review
por: Hesamizadeh, Khashayar, et al.
Publicado: (2016)

The effect of Iran’s health transformation plan on hospital performance: Kerman province
por: Goudarzi, Reza, et al.
Publicado: (2021)

Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals era
por: Hariri, Sanam, et al.
Publicado: (2020)

Liver Disease Burden of Hepatitis C Virus Infection in Iran and the Potential Impact of Various Treatment Strategies on the Disease Burden
por: Hajarizadeh, Behzad, et al.
Publicado: (2016)

How Can We Make Decision for Patients With Chronic Hepatitis B According to Hepatitis B Virus (HBV) DNA Level?
por: Keshvari, Maryam, et al.
Publicado: (2014)

What is the ethnicity-specific impact of genetic polymorphisms on the response to hepatitis C treatment in an admixed population of Brazilian patients?
por: Keshvari, Maryam, et al.
Publicado: (2014)

Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1
por: Sharafi, Heidar, et al.
Publicado: (2015)

Comparison of Serum Hepatitis B Virus DNA and HBsAg Levels Between HBeAg-Negative and HBeAg-Positive Chronic Hepatitis B Patients
por: Keshvari, Maryam, et al.
Publicado: (2015)

Cost-effectiveness analysis of coronary arteries bypass grafting (CABG) and percutaneous coronary intervention (PCI) through drug stent in iran: a comparative study
por: Fakhrzad, NourolHoda, et al.
Publicado: (2023)

Prevalence of Hepatitis B and Hepatitis C Infections among Incarcerated Individuals in Iran: A Cross-Sectional National Bio-behavioral Study in 2019
por: Moradi, Ghobad, et al.
Publicado: (2021)

Hepatitis A Virus and Hepatitis E Virus Seroprevalence Among Blood Donors in Tehran, Iran
por: Hesamizadeh, Khashayar, et al.
Publicado: (2016)

The Impact of IFNL4 rs12979860 Polymorphism on Spontaneous Clearance of Hepatitis C; A Case-Control Study
por: Sharafi, Heidar, et al.
Publicado: (2014)

The interferon lambda 4 rs368234815 predicts treatment response to pegylated-interferon alpha and ribavirin in hemophilic patients with chronic hepatitis C
por: Keshvari, Maryam, et al.
Publicado: (2016)

Interferon Alpha-2b Therapy in Chronic Hepatitis Delta
por: Keshvari, Maryam, et al.
Publicado: (2014)

The ITPA and C20orf194 Polymorphisms and Hematological Changes During Treatment With Pegylated-Interferon Plus Ribavirin in Patients With Chronic Hepatitis C
por: Pouryasin, Mohammad, et al.
Publicado: (2016)

Mysterious Linkages Between Hepatitis C Virus Genotypes, Interleukin-28B Genotypes and Viral Clearance- A Meta-Analysis
por: Aalaei-Andabili, Seyed Hossein, et al.
Publicado: (2014)

The Distribution of Hepatitis C Virus Genotypes in Middle Eastern Countries: A Systematic Review and Meta-Analysis
por: Ghaderi-Zefrehi, Hossein, et al.
Publicado: (2016)

Increasing national trend of direct-acting antiviral discontinuation among people treated for HCV 2016–2021
por: Carson, Joanne, et al.
Publicado: (2023)

Systematic Review and Meta-Analysis of Global Prevalence of HBsAg and HIV and HCV Antibodies among People Who Inject Drugs and Female Sex Workers
por: Rashti, Roya, et al.
Publicado: (2020)

Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline
por: Alavian, Seyed Moayed, et al.
Publicado: (2016)

Factors Affecting Fertility Rate in Iran (Panel Data 1966-2013): A Survey Study
por: Sabermahani, Asma, et al.
Publicado: (2017)

A Comparative Study on Willingness to Pay for Breast Cancer and Osteoporosis Screening in Kerman, Southeastern Iran
por: SABERMAHANI, Asma, et al.
Publicado: (2017)

Development and Validation of a Simple, Rapid and Inexpensive PCR-RFLP Method for Genotyping of Common IL28B Polymorphisms: A Useful Pharmacogenetic Tool for Prediction of Hepatitis C Treatment Response
por: Sharafi, Heidar, et al.
Publicado: (2012)

Distribution of IL28B Genotypes in Iranian Patients with Chronic Hepatitis C and Healthy Individuals
por: Sharafi, Heidar, et al.
Publicado: (2012)

Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals
por: Hill, Andrew, et al.
Publicado: (2018)

On the Occasion of the World Hepatitis Day: World Hepatitis Day and Our Achievements and Responsibilities in Iran
por: Alavian, Seyed Moayed
Publicado: (2012)

A Cost-Utility Analysis of Different Antiviral Medicine Regimens in Patients With Chronic Hepatitis C Virus Genotype 1 Infection
por: Alavian, Seyed Moayed, et al.
Publicado: (2016)

Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam
por: Due, Ong The, et al.
Publicado: (2020)

Timely Hepatitis C RNA Testing and Treatment in the Era of Direct-Acting Antiviral Therapy among People with Hepatitis C in New South Wales, Australia
por: Yousafzai, Mohammad T., et al.
Publicado: (2022)

Provincial Human Development Index, a Guide for Efficiency Level Analysis: The Case of Iran
por: SABERMAHANI, Asma, et al.
Publicado: (2013)

Efficacy of Prolonged Treatment With Pegylated Interferon (Peg-IFN) and Ribavirin in Thalassemic Patients With Hepatitis C Who Relapsed After Previous Peg-IFN-Based Therapy
por: Sandoughdaran, Saleh, et al.
Publicado: (2015)

Tehran Hepatitis Conference: An International Meeting with the Goal of Middle East without Viral Hepatitis
por: Fathi, Meisam, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_juqbkhbluvigc5jrvpuoa6dv6f